Ebola Vaccine: Information about Ervebo®
A safe and effective vaccine is an important tool to protect frontline workers and prevent the introduction and spread of Ebola in the United States.
Ebola virus is a zoonotic pathogen that causes severe hemorrhagic fever in humans, known as Ebola virus disease (EVD). There are four species of Ebola virus that have been known to cause disease in humans. Of these, species Zaire ebolavirus (EBOV) is the most lethal, with case fatality rates of 70–90% if left untreated. EBOV is responsible for the majority of recorded EVD outbreaks. This includes the two largest EVD outbreaks in history, the 2014–2016 West Africa outbreak and the 2018 outbreak in eastern Democratic Republic of the Congo, where over 32,000 people were infected, and more than 13,600 deaths were reported.
Importation of EVD to the United States from an epidemic region through an infected traveler is a recognized risk with the potential for spread to other people. During the 2014–2016 Ebola outbreak in West Africa, 11 people were treated for EVD in the U.S., and two of them died. Nine of these cases were imported into the U.S. Two were domestic healthcare workers who were infected while caring for the first travel-associated EVD case diagnosed in the U.S. Both healthcare workers recovered.
Ervebo® (Ebola Zaire Vaccine, Live also known as V920, rVSVΔG-ZEBOV-GP or rVSV-ZEBOV) is approved by the U.S. Food and Drug Administration (FDA) for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older as a single dose administration. Ervebo® is a replication-competent, live, attenuated recombinant vesicular stomatitis virus (rVSV) vaccine manufactured by Merck. It is not possible to become infected with EBOV from the vaccine because the vaccine only contains a gene from the Ebola virus, not the whole virus. Specifically, it contains a gene for the EBOV glycoprotein that replaces the gene for the native VSV glycoprotein. Ervebo® does not provide protection against other species of Ebolavirus or Marburgvirus.
Antibody measurements are often used as a surrogate test to predict when protection by a vaccine can be expected. Clinical trials have shown that the vaccine elicits rapid antibody response in 14 days after a single dose. Clinical efficacy of the vaccine was supported by a randomized cluster (ring) vaccination study during the 2014–2016 outbreak in Guinea. In this study, 3,775 people in close contact with diagnosed EVD cases (contacts) and their close contacts (contacts of contacts) received immediate vaccination. No one who was vaccinated immediately developed EVD 10 or more days after vaccination.
The correlate of protection, or the specific immune response to the Ervebo® vaccine that closely relates to protection against infection with EBOV, is unknown and still being studied. The duration of protection by Ervebo® against EBOV is unknown. It is also not known whether it is effective when administered concurrently with antiviral medication, immune globulin, and/or blood or plasma transfusion.
Ervebo® is not commercially marketed in the U.S. but is currently stockpiled by the Assistant Secretary for Preparedness. The stockpiled Ervebo® can be made available for pre-exposure vaccination of individuals who fall into one of the three occupational categories:
- Ebola virus disease (EVD) responders: Individuals responding to an outbreak due to Ebola virus (species Zaire ebolavirus).
- Biosafety level 4 (BSL-4) workers: Laboratorians and support staff working at BSL-4 facilities with replication-competent Ebola virus (species Zaire ebolavirus) or with specimens suspected to contain replication-competent Ebola virus (species Zaire ebolavirus). Personnel working at non-BSL-4 facilities in the Laboratory Response Network may be eligible to receive Ervebo depending on specific circumstances of public health needs and the Ebola preparedness and/or response activities at such facilities.
- Healthcare personnel (HCP)*: HCP at federally designated Ebola Treatment Centers involved in the care and transport of patients infected or suspected to be infected with Ebola virus (species Zaire ebolavirus). HCP working at state-designated Ebola healthcare facilities or other facilities may be eligible to receive Ervebo depending on specific circumstances of public health needs and the Ebola preparedness and/or response activities at such facilities.
*Disclaimer: The mention of any product names or non-United States Government entities on CDC Ebola websites is not meant to serve as an official endorsement of any such product or entity by the CDC, the Department of Health and Human Service, or the United States Government.
- Ervebo® package insertexternal icon
- Ervebo® patient informationexternal icon
- Choi MJ, Cossaboom CM, Whitesell AN, et al. Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2021;70(No. RR-1):1–12. DOI: http://dx.doi.org/10.15585/mmwr.rr7001a1external iconexternal icon.
*Healthcare personnel (HCP) refers to all paid and unpaid persons serving in healthcare settings who have the potential for direct or indirect exposure to patients or infectious materials, including body substances (e.g., blood, tissue, and specific body fluids); contaminated medical supplies, devices, and equipment; contaminated environmental surfaces; or contaminated air. These HCP include, but are not limited to, emergency medical service personnel, nurses, nursing assistants, physicians, technicians, clinical laboratory personnel, autopsy personnel, therapists, phlebotomists, pharmacists, students and trainees, contractual staff not employed by the healthcare facility, and persons not directly involved in patient care, but who could be exposed to infectious agents that can be transmitted in the healthcare setting (e.g., clerical, dietary, environmental services, laundry, security, engineering and facilities management, administrative, billing, and volunteer personnel).